Home > Sponsor/Funder

Sponsor Specific Details: Sanofi

  • Studies listed

    Sanofi is committed to sharing clinical study data with external researchers, as articulated in the Pharmaceutical Research and Manufacturers of America (PhRMA) / European Federation of Pharmaceutical Industries and Associations (EFPIA) Principles for Responsible Clinical Trial Data Sharing.

    Data from interventional phase II - IV clinical studies will be made available for request through the portal
    - for products that have been approved on or after January 1, 2010 by both the US and EU Health Authorities, or by the US or EU Health Authorities when regulatory submissions are not planned in both regions;
    - for products which development has been terminated on or after January 1, 2010 (i.e. formally confirmed as excluded from any further internal or external development activities).

    Within the product scope defined above, a clinical trial (interventional study) will be listed as available for request through the portal when the trial meets the following criteria:
    - the trial has been completed (or terminated after patients were enrolled);
    - and the primary trial results have been accepted for publication and in exceptional circumstances assessed by study sponsor, only after key secondary results have been accepted for publication;
    - or, in the absence of a publication, when the trial results have been made publicly available.

    Data from clinical studies for co-developed products approved on or after Jan 1, 2010, and from clinical studies for products which development has been terminated on or after Janury 1, 2010 that are not listed on the portal, can be requested by completing the online enquiry form as described below. All requests will be reviewed and a decision made on a case-by-case basis.

  • Exceptions

    Sanofi will not list studies when one of the following conditions applies:

    Sanofi believes that the privacy and confidentiality of research participants cannot be protected through anonymization, e.g. single site studies, genetic/genomic data, or studies in rare diseases.

    There are legal or contractual agreements in place that would limit our ability to list the study and share the data with a third party, such as when the medicine has been out-licensed to another company, the data are the property of another organization, the data originate from third party databases under license agreements which prevent Sanofi from providing access.

    There are substantial practical/technical constraints to providing the data. Examples include: data are not available in electronic format or data are images (e.g., X-Ray/MRI scan).

    The data labels and/or supporting documents are not in English.

  • When studies are listed

    Clinical trials will be eligible for listing once the above criteria in "Studies listed" are met and none of the "Exceptions" above apply.

    Sanofi will regularly update this list to add trials meeting the criteria. An enquiry can be submitted for studies that are not yet listed.

  • Additional conditions for data access

    Prior to 2014, when patients agreed to take part in Sanofi clinical trials they gave Sanofi permission (through informed consent) to use their data to study the medicine or disease being researched. Therefore, Sanofi will require that any use of these data by a third party must address a scientific question in the same disease area as the original trial. For Sanofi clinical trials initiated in 2014 and onward, patients have been asked to give permission for broader research beyond the original trial intent, so research on other disease areas may be possible with data from these trials.

    In exceptional circumstances, access to data may be declined by the study sponsor, for example, where there is a potential conflict of interest or an actual or potential competitive risk.

  • Datasets and documents provided

    Where available, the following anonymized patient level data and information is provided for each clinical trial:

    Raw dataset. This is the raw data collected for each patient in the clinical trial

    Analysis-ready dataset. This is the dataset Sanofi used for analysis

    Protocols with any amendments. This describes the objectives, design, methodology, statistical considerations, and organization of a clinical trial

    Annotated case report form. This is a blank case report form with descriptions of the data collected and how they are described in the dataset

    Statistical methods. This describes methods of analysis and procedures for data handling

    Dataset specifications. This is the meta-data which describes the datasets, e.g., variable labels, variable descriptions, code lists, formats

    Clinical Study Report. This is the report of efficacy and safety data from the trial. It forms the basis of submissions to Health Authorities. Appendices which include patient level data are not included as these data are provided in the anonymized datasets.
  • Enquiries

    Researchers may enquire about the availability of data from Sanofi clinical trials that are not listed on the site by completing the online enquiry form. This includes enquiries for access to data of trials of products approved prior to January 1, 2010, Phase I trials, unlisted trials for products which development has been terminated, and trials for co-developed products. All enquiries will be considered on a case-by-case basis.

  • Access to study documents without patient-level data

    Researchers can enquire about access to clinical study documents such as the Clinical Study Report by completing the online enquiry form.

  • Review criteria for enquiries

    Sanofi will conduct a feasibility assessment for all enquiries received, based upon the criteria described below:

    Whether the requested studiesare for a product that has been approved by the Health Authorities, or for a product which development has been terminated (see section "When studies are listed").

    Whether the studies are completed (or terminated after patients were enrolled) and the primary study results (and in exceptional circumstances key secondary results) have been accepted for publication, or, if a publication is not feasible, the results have been made publicly available.

    Whether Sanofi believes that the privacy and confidentiality of research participants cannot be protected through anonymization, e.g. single site studies, genetic/genomic data, or studies in rare diseases.

    Whether there are legal or contractual agreements in place that would limit our ability to list the study and/or share the data with a third party, such as when the medicine has been out-licensed to another company, the data are the property of another organization, the data originate from third party databases under license agreements which prevent Sanofi from providing access.

    Whether there are substantial practical/technical constraints to providing the data. Examples include: data are not available in electronic format or data are images (e.g., X-Ray/MRI scan).

    Whether the data labels and/or supporting documents are not in English.

    Please be aware that the feasibility assessment for older compounds/studies may require additional lead times due to legal and operational constraints.

  • Anonymisation standards